Black Titan Completes Titan Pharma Acquisition, Launches on Nasdaq
Black Titan Corporation has acquired Titan Pharmaceuticals, Inc., making it a wholly owned subsidiary. Trading of Titan's common stock ceased on October 1, 2025, and Black Titan's ordinary shares began trading on the Nasdaq stock market under the ticker symbol NASDAQ: BTTC.
The merger, completed on October 1, 2025, saw each share of Titan common stock converted into ordinary shares of Black Titan on a one-for-one basis. ARC Group Ltd. served as the exclusive financial advisor to Black Titan throughout the transaction, which also involved TalenTec Sdn. Bhd.
Chay W. J., CEO of Black Titan, hailed the merger as the start of a new era, promising innovation and global expansion.
Following the merger, Titan Pharmaceuticals, Inc. (TTNP) is now a subsidiary of Black Titan Corporation. The new company's ordinary shares trade on the Nasdaq under the ticker symbol NASDAQ: BTTC, marking a significant step in Black Titan's growth.
Read also:
- Eric Dane Diagnosed with ALS, Advocates for ACT for ALS
- Deepwater Horizon Oil Spill: BP Faces Record-Breaking Settlement - Dubbed 'Largest Environmental Fine Ever Imposed'
- Meta Unveils Ray-Ban AR Display Sunglasses; TikTok Agrees to $200 Million Deal
- Historic downtown temples to receive restoration funds totaling over 25 million pesos
